Drug Yields High Response Rates for Lung Cancer Patients With Harsh Mutation

Excerpt:

“A targeted therapy resurrected by the Moon Shots Program™ at The University of Texas MD AndersonCancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries a highly treatment-resistant mutation.

“In a phase 2 clinical trial, the drug poziotinib has shrunk tumors by at least 30 percent in eight of 11 (73 percent) non-small cell lung cancer patients whose cancer includes an epidermal growth factor receptor (EGFR) mutation called an exon 20 insertion.  Shrinkage ranged from 30 percent to 50 percent among the eight patients reaching partial response.  One patient has progressed on the clinical trial, which began in March.  All patients experienced some tumor shrinkage.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.